Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rintatolimod + interferon alfa-2b + celecoxib (Roswell Park Comprehensive Cancer Center)
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
The Chemokine Modulatory Regimen (CKM) is an investigational combination immunotherapy developed at Roswell Park Comprehensive Cancer Center. It consists of three active components: rintatolimod (a selective TLR3 agonist), interferon alfa-2b (a cytokine), and celecoxib (a COX-2 inhibitor). The regimen is designed to reprogram the tumor microenvironment by selectively inducing the production of cytotoxic T lymphocyte (CTL)-attracting chemokines, such as CXCL9, CXCL10, and CCL5. By increasing the infiltration of CD8+ T cells, CKM aims to convert immunologically "cold" tumors into "hot" tumors, potentially enhancing the efficacy of other immunotherapies. It has been evaluated in Phase 1 and 2 clinical trials for various solid tumors, including colorectal cancer, triple-negative breast cancer, and melanoma.
- Other names
- chemokin modulatory regimenChemokine Modulatory RegimenCKM regimen
02
Targets
TLR3 (Toll-like receptor 3)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on rintatolimod + interferon alfa-2b + celecoxib (Roswell Park Comprehensive Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rintatolimod + interferon alfa-2b + celecoxib (Roswell Park Comprehensive Cancer Center).